A practical radiosynthesis of a tritium‐labelled fluorocombretastatin | Zendy

Hadfield John A. | Zendy; Hirst Nicholas | Zendy; Gaukroger Keira | Zendy; Lawrence Nicholas J. | Zendy; McGown Alan T. | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

A practical radiosynthesis of a tritium‐labelled fluorocombretastatin

Author(s) -

Hadfield John A.,

Hirst Nicholas,

Gaukroger Keira,

Lawrence Nicholas J.,

McGown Alan T.

Publication year - 2012

Publication title -

journal of labelled compounds and radiopharmaceuticals

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.432

H-Index - 47

eISSN - 1099-1344

pISSN - 0362-4803

DOI - 10.1002/jlcr.2939

Subject(s) - radiosynthesis , chemistry , tritium , radiochemistry , combinatorial chemistry , chemical synthesis , in vitro , biochemistry , nuclear medicine , positron emission tomography , medicine , physics , nuclear physics

Zybrestat (combretastatin A‐4 disodium diphosphate) is currently in clinical trials as an antivascular anticancer agent. A similar fluorinated agent has shown promise as an antivascular agent, and a radiolabelled version would enable further understanding of its biological activities. Herein is described the synthesis of a tritiated fluorinated analogue of Zybrestat. Copyright © 2012 John Wiley & Sons, Ltd.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research